Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 10/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28608485 | 0.75 | MTNR1A (0.37) | MTNR1AMTNR1BADRA2AADRA2BADRA2C | |
| SCHEMBL5374308 | 0.75 | FGFR1 (0.47) | MTNR1AMTNR1BADRA2AADRA2BADRA2C | |
| SCHEMBL27858072 | 0.75 | MTNR1A (0.35) | MTNR1AMTNR1BADRA2AADRA2BADRA2C | |
| SCHEMBL28371568 | 0.74 | MTNR1A (0.43) | MTNR1AMTNR1BADRA2AADRA2BADRA2C | |
| SCHEMBL4915638 | 0.74 | MTNR1A (0.38) | MTNR1AMTNR1BADRA2AADRA2BADRA2C | |
| SCHEMBL4795332 | 0.70 | ADRA1A (0.44) | ADRA2AOPRM1 | |
| Acenaphthene SCHEMBL28276761 | 0.70 | ADRA2A (0.43) | MTNR1AMTNR1BADRA2AADRA2BADRA2C | |
| SCHEMBL21221316 | 0.70 | FGFR1 (0.40) | MTNR1AMTNR1BADRA2AADRA2BADRA2C | |
| SCHEMBL28439243 | 0.70 | MTNR1A (0.38) | MTNR1AMTNR1BADRA2AADRA2BADRA2C | |
| SCHEMBL13004830 | 0.69 | MTNR1A (0.40) | MTNR1AMTNR1BADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311844-B | Triazine compound, method for producing same, and organic electroluminescent element containing same as constituent component | 东曹株式会社 | 2021-07-20 | — | — | CN | disclosed |
| US-20080287695-A1 | Agent For Optical Resolution, Process For Producing Optically Active Substance and 1,5-Substituted Bicyclo [3.3.0] -2-Oxaoctane Compound | ZEON CORPORATION (JP) | 2008-11-20 | — | — | US | disclosed |
| EP-1719746-A1 | OPTICAL RESOLVER, PROCESS FOR PRODUCING OPTICALLY ACTIVE ISOMER, AND 1,5-SUBSTITUTED BICYCLO (3.3.0) -2-OXAOCTANE COMPOUND | ZEON CORPORATION (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287695-A1 | Agent For Optical Resolution, Process For Producing Optically Active Substance and 1,5-Substituted Bicyclo [3.3.0] -2-Oxaoctane Compound | ALDH1A2, OXER1, HCRTR1 | MTNR1A 676/4885MTNR1B 633/4885ADRA2A 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.